Mayzent (Siponimod) vs Fleqsuvy (baclofen)

Mayzent (Siponimod) vs Fleqsuvy (baclofen)

Mayzent (Siponimod) is a sphingosine 1-phosphate receptor modulator specifically approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Fleqsuvy (Baclofen) is a muscle relaxer and an antispastic agent primarily used to treat muscle spasticity in conditions such as multiple sclerosis and spinal cord injury. When deciding between Mayzent and Fleqsuvy, it is important to consider that Mayzent targets the underlying disease process in MS, while Fleqsuvy is used to manage specific symptoms such as muscle spasms, and the choice would depend on the individual's specific medical condition and treatment goals.

Difference between Mayzent and Fleqsuvy

Metric Mayzent (Siponimod) Fleqsuvy (baclofen)
Generic name Siponimod Baclofen
Indications Multiple sclerosis (specifically for secondary progressive forms) Muscle spasticity
Mechanism of action Sphingosine 1-phosphate receptor modulator GABA-B receptor agonist
Brand names Mayzent Fleqsuvy, Lioresal
Administrative route Oral Oral, intrathecal
Side effects Headache, hypertension, liver function test abnormalities, bradycardia Drowsiness, dizziness, weakness, fatigue, headache, insomnia, nausea
Contraindications CYP2C9*3/*3 genotype, recent myocardial infarction, stroke, or heart failure Kidney disease, epilepsy, history of stroke or blood clots, if using an intrathecal pump
Drug class Sphingosine 1-phosphate receptor modulator Antispastic agent
Manufacturer Novartis Various

Efficacy

Efficacy of Mayzent (Siponimod) in Multiple Sclerosis

Mayzent (Siponimod) is a medication specifically approved for the treatment of multiple sclerosis (MS), particularly for relapsing forms of the disease, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The efficacy of Mayzent in MS is primarily attributed to its mechanism of action as a sphingosine-1-phosphate receptor modulator. This action leads to the sequestration of lymphocytes in lymph nodes, preventing them from contributing to the central nervous system inflammation that characterizes MS.

Clinical trials have demonstrated that Mayzent can significantly reduce the annual relapse rate in patients with relapsing forms of MS. Furthermore, Mayzent has been shown to delay the progression of disability associated with MS and reduce the number of new or enlarging brain lesions detected by magnetic resonance imaging (MRI). These benefits make Mayzent a valuable treatment option for individuals with relapsing forms of MS, aiming to manage the disease's progression and maintain quality of life.

Efficacy of Fleqsuvy (Baclofen) in Multiple Sclerosis

Fleqsuvy (Baclofen) is not primarily indicated for multiple sclerosis; however, it is commonly used off-label to manage certain symptoms associated with MS, particularly spasticity. Spasticity is a common symptom in MS patients, characterized by muscle stiffness and involuntary muscle spasms. Baclofen is a muscle relaxant and an agonist at the GABA-B receptors in the brain and spinal cord, which helps alleviate these symptoms.

While the direct impact of Fleqsuvy on the progression of MS has not been established, its efficacy in managing spasticity can significantly improve the quality of life for patients with MS. Clinical experience and reports suggest that baclofen effectively reduces the severity of spasticity, allowing for better mobility and reduced discomfort. However, it is essential to note that the use of baclofen for MS-related spasticity should be carefully managed by healthcare professionals to optimize dosing and minimize potential side effects.

Regulatory Agency Approvals

Mayzent
  • European Medical Agency (EMA), European Union
  • Food and Drug Administration (FDA), USA
  • Therapeutic Goods Administration (TGA), Australia
Fleqsuvy
  • Food and Drug Administration (FDA), USA

Access Mayzent or Fleqsuvy today

If Mayzent or Fleqsuvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email:

Contact us
US United States 1